Dense Breasts and Supplemental Screening: What Does the Guidance Actually Say?

During Breast Cancer Awareness Month, one question reaches clinics and helplines more than almost any other in breast screening: “My mammogram report says I have dense breasts. Do I need more tests?” The answer is less simple than many women expect, and it depends on where you live. In the United States, a federal rule now requires every mammography facility to tell you whether your breasts are dense, and the letter itself suggests that extra imaging may help in some cases. In the United Kingdom, women attending routine NHS breast screening are not told their breast density and are not routinely offered additional imaging. Both positions come from real guidance rather than oversight, and both rest on an honest uncertainty about what supplemental screening can and cannot do. This article sets out what “dense breasts” means, why it matters in two different ways, what the US and UK guidance actually say, which extra tests exist, and what to ask your own clinician.

What does “dense breasts” actually mean?

Breasts contain fatty tissue and fibroglandular tissue (milk glands, ducts and supporting connective tissue). On a mammogram, fatty tissue looks dark and fibroglandular tissue looks white. “Density” describes how much of the breast is fibroglandular tissue relative to fat. Radiologists use four standard categories, known as the BI-RADS density categories:

The breasts are almost entirely fatty.
There are scattered areas of fibroglandular density.
The breasts are heterogeneously dense, which may obscure small masses.
The breasts are extremely dense, which lowers the sensitivity of mammography.

Categories 3 and 4 are what clinicians mean by “dense breasts”. Roughly half of US women aged 40 and older who have mammograms fall into one of these two categories, according to the National Cancer Institute. It is a normal, common imaging finding: not a diagnosis and not a disease. You cannot tell whether your breasts are dense by how they look or feel; only a mammogram shows it. Density also changes over time. It tends to fall with age and can shift with hormones, body composition and medication.

Why does breast density matter? Two separate reasons

First, masking. Both dense tissue and many cancers appear white on a mammogram, so a tumour can be hidden against the surrounding tissue. Hospital guidance illustrates the scale: in extremely dense breasts, mammography may miss around 40 percent of cancers present, and around 25 percent in heterogeneously dense breasts.

Second, risk. Dense tissue is associated with a moderately higher chance of developing breast cancer. Clinical reviews commonly cite roughly a fourfold higher risk for extremely dense breasts compared with almost entirely fatty breasts, and about double the risk compared with scattered fibroglandular tissue, though estimates vary between studies. It is worth stressing that density is one risk factor among many, and that most women with dense breasts never develop breast cancer.

These two issues are often confused. Density can both hide a cancer on the image and independently raise the underlying likelihood of cancer. Keeping them separate helps explain why guidance in different countries diverges.

What does the US guidance say?

In March 2023 the US Food and Drug Administration issued a final rule updating the Mammography Quality Standards Act, with compliance required from 10 September 2024. Every mammography facility in the country must now include a standardised statement in the letter sent to each patient, saying whether her breast tissue is “dense” or “not dense”. For women with dense breasts, the letter must explain that dense tissue makes it harder to find breast cancer on a mammogram, that it raises the risk of developing breast cancer, and that “in some people with dense tissue, other imaging tests in addition to a mammogram may help find cancers.” It also encourages the woman to talk with her healthcare provider. The same rule requires the report sent to the referring clinician to use the four formal density categories.

But the US rule does not, by itself, recommend extra screening for every woman with dense breasts. The US Preventive Services Task Force concludes that the evidence is insufficient to recommend for or against supplemental ultrasound or MRI solely because a person has dense breasts after an otherwise negative mammogram. In other words, the US position is: you must be told, and then you and your clinician decide.

What happens in practice is mixed. A 2026 analysis of US insurance claims, reported in August 2026, found that state notification laws were associated with higher use of breast ultrasound after mammography, especially where the notice itself mentioned supplemental screening. Insurance mandates had the strongest effect, raising ultrasound use around four times more than notification alone. Even so, only about 9 percent of women received a supplemental ultrasound within six months of screening, and under 1 percent received an MRI, despite more than 40 percent of middle-aged and older women having dense breasts. Older women, rural women and those with other health conditions were less likely to get follow-up imaging, suggesting that access and cost barriers matter as much as information.

The American College of Radiology recommends annual mammography from age 40 for average-risk women, and advises a formal breast cancer risk assessment by age 25 to identify those who need earlier or additional screening.

What does the NHS guidance say?

The UK position is strikingly different. Women attending routine NHS breast screening are not informed whether they have dense breasts, and they are not routinely offered additional imaging on density grounds. This is a deliberate policy, not an omission. In a written answer to Parliament in February 2026, the government explained that screening programmes are guided by the independent advice of the UK National Screening Committee, which only recommends screening where there is robust evidence that the benefits outweigh the harms. It noted that dense breast tissue reduces mammographic accuracy and that unnecessary diagnostic tests can cause harm and distress.

The UK National Screening Committee is actively reviewing the question. A written answer in October 2025 confirmed the committee is considering risk stratification in breast screening, including whether women with denser breasts should have a different screening approach, with research work under way on the issue.

The evidence base is growing. The BRAID trial, published in The Lancet in 2025 and involving more than 9,000 women including patients of the Royal Free London screening service, tested alternative scans in women with very dense breasts whose mammograms had been reported as normal. It found that two alternative methods, contrast-enhanced mammography and a fast (abbreviated) MRI scan, detected 17 to 19 cancers per 1,000 women screened, compared with eight per 1,000 for traditional mammography. The researchers estimated that using these techniques for women with very dense breasts could identify around 3,500 extra cancers a year in the UK and potentially save 700 lives.

At the same time, there is evidence that notification without a clear pathway can do harm. An Australian clinical trial published in The BMJ found that women who were told they had dense breasts felt more anxious and confused about their breast health eight weeks after screening and were more likely to seek GP advice about what to do next, despite the lack of clear, evidence-based and equitable clinical pathways. The researchers concluded that population-wide breast density notification “should be carefully considered owing to potential adverse outcomes.” A UK campaign, Dense Breast Inform, continues to call on the Department of Health and Social Care to change the policy, with backing from MPs across parties.

For now, the NHS position remains: routine screening invitations for women aged 50 to 71 every three years, no density notification, no routine supplemental imaging, with the question under formal review.

What supplemental screening options exist?

Where extra imaging is offered, three main options are discussed:

Breast ultrasound: can find some cancers mammography misses. A handheld scan depends on the operator; automated breast ultrasound (ABUS) standardises the technique. A 2026 US study funded by the National Cancer Institute found ABUS had fewer false alarms than handheld scans in dense breasts with no apparent drop in cancer detection, for women already having supplemental ultrasound.
Abbreviated (fast) MRI: detects more cancers in dense breasts but increases false positives, requires contrast dye, takes longer, and is expensive with limited availability.
Contrast-enhanced mammography: performed like a standard mammogram with a contrast injection; showed similar detection gains to fast MRI in the BRAID trial.

Every option has trade-offs. More tests mean more false positives, more biopsies, more anxiety, more cost and, in some settings, contrast risks. That is why both the US and UK guidance frame the decision around individual risk rather than density alone.

What should you do if you are told you have dense breasts?

First, know that a dense result is common and not an emergency. The sensible next step is a conversation about your overall breast cancer risk, not automatic additional testing. Useful questions to bring:

What is my density category, and has it changed since my last mammogram?
Given my family history, genetics, age and previous imaging, is supplemental screening appropriate for me?
If extra imaging is suggested, which type do you recommend and why?
What would the costs, false-positive rate and follow-up involve?

Stay breast aware regardless of density. Know what is normal for you and report a new lump, skin changes, nipple discharge or persistent pain to your GP promptly, even if a recent screen was normal. Screening tests are designed for people without symptoms; they do not replace seeking care for a change you can feel. For readers in midlife, our guide to perimenopause and mental health and our explainer on menopause and brain health cover other health questions women commonly bring to their GP at this stage of life. For background on the official position, see the FDA’s own explainer on breast density.

Frequently asked questions

Do I need extra screening if I have dense breasts?
Not automatically. Guidance on both sides of the Atlantic says extra imaging should be based on your overall risk, not density alone. In the US, the FDA requires you to be told your density so you can discuss options with your clinician; the USPSTF does not recommend for or against supplemental screening on density alone after a normal mammogram. In the UK, supplemental imaging is not offered routinely and the question is under review.

Does having dense breasts mean I will get breast cancer?
No. Density is associated with a moderately higher risk, but most women with dense breasts never develop breast cancer. It is one factor among many, including age, family history, genetics and reproductive history.

Why does the NHS not tell women their breast density?
The NHS Breast Screening Programme is guided by the UK National Screening Committee, which only adds screening where there is robust evidence that benefits outweigh harms. The committee is currently considering whether women with denser breasts should have a different screening approach. A UK campaign continues to press for change, citing US practice and the BRAID trial.

What is the difference between heterogeneously dense and extremely dense breasts?
Both count as “dense breasts”. Heterogeneously dense means much of the breast is dense tissue, which may hide small masses. Extremely dense means almost all the breast is fibroglandular tissue, which lowers mammography sensitivity the most and carries the higher risk estimate of the two.

How can I find out my breast density in the UK?
Routine NHS screening results do not currently include density. You can ask the screening service or your GP, though there is no formal pathway for reporting it. If you have private screening, the radiology report may state the BI-RADS density category. Either way, density alone does not determine your screening plan.